The Effect of PPB Using 10, 20 and 30 ml of Lidocaine, Study on Volunteers

Sponsor
Charlotte Runge (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05464862
Collaborator
Danish Society of Anesthesiology and Intensive Care Medicine DASAIM (Other), University of Aarhus (Other), The Danish Rheumatism Association (Other)
40
1
5
36
1.1

Study Details

Study Description

Brief Summary

The aim of this study is to evaluate the Popliteal Plexus Block (PPB) effect on motor nerve branches of the sciatic and femoral nerve, when using different volumes of local anesthetics for PPB.

The hypothesis is that increasing the volume of anesthetics used for PPB will spread to the sciatic nerve leading to a reduced muscle strength in the lower leg and decreased nerve conduction velocity in the nerve to gastrocnemius muscle (the tibial nerve) and the nerve to anterior tibial muscle (the deep fibular nerve).

The effects will be evaluated by maximum voluntary isometric contraction (MVIC) of the lower leg muscles and by recordings of the compound muscle action potential (cMAP) of the gastrocnemius and tibialis anterior muscles - a motor nerve conduction study.

In addition, evaluation of PPBs effect on the femoral nerve is done by MVIC of the quadriceps femoris muscle, cMAP of the vastus medialis and vastus lateralis muscles and by a sensory nerve conduction study of the saphenous nerve.

Condition or Disease Intervention/Treatment Phase
  • Drug: Lidocaine Hydrochloride 10 MG/ML [Xylocaine]
  • Drug: Lidocaine Hydrochloride 10 MG/ML [Xylocaine]
  • Drug: Lidocaine Hydrochloride 10 MG/ML [Xylocaine]
  • Drug: Lidocaine Hydrochloride 10 MG/ML [Xylocaine]
  • Drug: Lidocaine Hydrochloride 10 MG/ML [Xylocaine]
Phase 4

Detailed Description

A total number of 40 volunteers will be enrolled in the study. Each volunteer will receive two peripheral nerve blocks (one in each leg) on the day of participation. This will result in 80 peripheral nerve blocks. The types of nerve blocks given to each leg on each volunteer will depend on randomization.

The 80 nerve blocks are divided into five groups specified by type of nerve block, volume of anesthetic used, and respective numbers of legs used in the group. The groups and specifications are listed here:

Groups name, type of peripheral nerve block, study medication dosage and number of legs in the group:

  • Group A: PPB with 10 ml of lidocaine 1%, 20 legs.

  • Group B: PPB with 20 ml of lidocaine 1%, 20 legs.

  • Group C: PPB with 30 ml of lidocaine 1%, 20 legs.

  • Group FNB: FNB with 20 ml of lidocaine 1%, 10 legs.

  • Group SNB: SNB with 20 ml of lidocaine 1%, 10 legs.

Group FNB of SNB are performed unblinded and works as active comparatives for model control, in order to establish reference points for when a nerve is considered affected.

Prior to nerve block procedure , pre block assessments are obtained in the following order:
  • Sensory test of the saphenous nerve.

  • MVIC by ankle plantarflexion.

  • MVIC by ankle dorsiflexion.

  • MVIC by knee extension.

  • Compound muscle action potential (cMAP) recordings in the following order:

  • Nerve to vastus medialis muscle

  • Nerve to vastus lateralis muscle

  • Nerve to tibialis anterior muscle

  • Nerve to gastrocnemius muscle

60 minutes after the block performance, post block assessments are done. Values are obtained in the same order as for the pre block assessments.

A peripheral intravenous line is inserted prior to the procedure of the peripheral nerve block is performed. At the discretion of the anesthetist, up to 20 mg Propofol IV may be provided to ease the patient during the nerve block procedure. The volunteer is monitored with continuous electrocardiography and pulse oximetry for the first 30 minutes after block performance and clinically hereafter. Final check by an investigator to ensure the volunteer is ready to go home. If the muscle strength is reduced, the volunteer will not be sent home before the ability to walk safely with crutches is ensured.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
A person, not otherwise involved in the study will perform a randomization list. The list will contain the ID number (1-40), assigned group and type of nerve block and volume of Lidocaine 1% to be administered for nerve block, e.g. ID nr. 1: Right leg = Group A, PPB with 10 ml of lidocaine 1% Left leg = Group SNB, SNB with 20 ml of lidocaine 1% Randomization must ensure that the legs of a volunteer cannot be assigned to the same group. Groups name, type of peripheral nerve block, study medication dosage and number of legs in the group: Group A: PPB with 10 ml of lidocaine 1%, 20 legs. Group B: PPB with 20 ml of lidocaine 1%, 20 legs. Group C: PPB with 30 ml of lidocaine 1%, 20 legs. Group FNB: FNB with 20 ml of lidocaine 1%, 10 legs. Group SNB: SNB with 20 ml of lidocaine 1%, 10 legs.A person, not otherwise involved in the study will perform a randomization list. The list will contain the ID number (1-40), assigned group and type of nerve block and volume of Lidocaine 1% to be administered for nerve block, e.g. ID nr. 1: Right leg = Group A, PPB with 10 ml of lidocaine 1% Left leg = Group SNB, SNB with 20 ml of lidocaine 1% Randomization must ensure that the legs of a volunteer cannot be assigned to the same group.Groups name, type of peripheral nerve block, study medication dosage and number of legs in the group:Group A: PPB with 10 ml of lidocaine 1%, 20 legs. Group B: PPB with 20 ml of lidocaine 1%, 20 legs. Group C: PPB with 30 ml of lidocaine 1%, 20 legs. Group FNB: FNB with 20 ml of lidocaine 1%, 10 legs. Group SNB: SNB with 20 ml of lidocaine 1%, 10 legs.
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
As different volumes are used for the nerve blocks, the anesthesiologist and an assistant performing the nerve blocks will not be blinded, and therefore have no further contact with the volunteers after the nerve block performance and will not contribute with the data collection or statistical analysis. The nerve block procedure and assessments will take place in different rooms; hence the data collecting assessors will not be present during block performance.To ensure blinding of the volunteer, a draping will hinder the volunteer from observing which volume of lidocaine that is administered during block performance.Group A, B and C are blinded until the data analysis is finished. Group FNB of SNB are unblinded and works as active comparatives for model control, in order to establish reference points for when a nerve is considered affected.
Primary Purpose:
Treatment
Official Title:
The Effect of the Popliteal Plexus Block on the Motor Function of the Leg - a Randomized, Controlled, Blinded Study in Volunteers
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Sep 1, 2025
Anticipated Study Completion Date :
Sep 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Group A

Popliteal Plexus Block given with 10 ml of Lidocaine Hydrochloride 10 mg/ml

Drug: Lidocaine Hydrochloride 10 MG/ML [Xylocaine]
Ultrasound-guided Popliteal Plexus Block using 10 ml of of Lidocaine Hydrochloride 10 mg/ml
Other Names:
  • Popliteal Plexus Block
  • Experimental: Groups B

    Popliteal Plexus Block given with 20 ml of Lidocaine Hydrochloride 10 mg/ml

    Drug: Lidocaine Hydrochloride 10 MG/ML [Xylocaine]
    Ultrasound-guided Popliteal Plexus Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml
    Other Names:
  • Popliteal Plexus Block
  • Experimental: Group C

    Popliteal Plexus Block given with 30 ml of Lidocaine Hydrochloride 10 mg/ml

    Drug: Lidocaine Hydrochloride 10 MG/ML [Xylocaine]
    Ultrasound-guided Popliteal Plexus Block using 30 ml of of Lidocaine Hydrochloride 10 mg/ml
    Other Names:
  • Popliteal Plexus Block
  • Active Comparator: Group FNB

    Femoral Nerve Block given with 20 ml of Lidocaine Hydrochloride 10 mg/ml

    Drug: Lidocaine Hydrochloride 10 MG/ML [Xylocaine]
    Ultrasound-guided Femoral Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the femoral nerve.
    Other Names:
  • Femoral Nerve Block
  • Active Comparator: Groups SNB

    Sciatic Nerve Block given with 20 ml og Lidocaine Hydrochloride 10 mg/ml

    Drug: Lidocaine Hydrochloride 10 MG/ML [Xylocaine]
    Ultrasound-guided Sciatic Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the sciatic nerve.
    Other Names:
  • Sciatic Nerve Block
  • Outcome Measures

    Primary Outcome Measures

    1. MVIC (Maximum Voluntary Isometric Contraction) ankle plantarflexion [Measured pre block and at 60 minutes post block]

      Difference between group A, B and C in post block MVIC by ankle plantarflexion, expressed as percentage change of the pre block value. MVIC is measured using a handheld dynamometer.

    2. MVIC ankle dorsiflexion [Measured pre block and at 60 minutes post block]

      Difference between group A, B and C in post block MVIC by ankle dorsiflexion, expressed as a percentage change of the pre block value. MVIC is measured using a handheld dynamometer.

    Secondary Outcome Measures

    1. MVIC knee extension [Measured pre block and at 60 minutes post block]

      Difference between group A, B and C in post block MVIC by knee extension, expressed as a percentage change of the pre block value. MVIC is measured using a handheld dynamometer.

    2. cMAP (compoud motor action potention) gatrocnemius [Measured pre block and at 60 minutes post block]

      Difference between group A, B and C, in the number of volunteers with affected cMAP of the gastrocnemius muscle, defined as sufficient change from pre block to post block. Cut-off value for sufficient change is determined by SNB group. cMAP is recorded using a motor nerve conduction study.

    3. cMAP tibialis anterior [Measured pre block and at 60 minutes post block]

      Difference between group A, B and C, in the number of volunteers with affected cMAP of the tibialis anterior muscle, defined as sufficient change from pre block to post block. Cut-off value for sufficient change is determined by SNB group. cMAP is recorded using a motor nerve conduction study.

    4. cMAP vastus medialis [Measured pre block and at 60 minutes post block]

      Difference between group A, B and C, in the number of volunteers with affected cMAP of the vastus medialis muscle, defined as sufficient change from pre block to post block. Cut-off value for sufficient change is determined by FNB group. cMAP is recorded using a motor nerve conduction study.

    5. cMAP vastus lateralis [Measured pre block and at 60 minutes post block]

      Difference between group A, B and C, in the number of volunteers with affected cMAP of the vastus lateralis muscle, defined as sufficient change from pre block to post block. Cut-off value for sufficient change is determined by FNB group. cMAP is recorded using a motor nerve conduction study.

    6. Saphenus senory test [Measured pre block and at 60 minutes post block]

      Difference between group A, B and C in the number of volunteers with an affected sensory of the saphenous nerve, defined as change, from pre block to post block, in the volunteers ability to discriminate cold in the cutaneous area innervated by the medial crural cutaneous branches of saphenous nerve.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • ASA 1-2

    • Ability to give their written informed consent to participating in the study after having fully understood the contents of the study

    Exclusion Criteria:
    • Subjects who cannot cooperate with the study.

    • Subjects who cannot understand or speak Danish.

    • Subjects with allergy to the medicines used in the study.

    • Subjects suffering from alcohol and/or drug abuse - based on the investigator's opinion.

    • Pathology or previous surgery to the lower limb.

    • Intake of any analgesics 24 hours prior to baseline measurements.

    • BMI > 30

    • Pregnancy status, provided by the volunteer.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Elective Surgery Center at Silkeborg Regional Hospital Silkeborg Region Midt Denmark 8600

    Sponsors and Collaborators

    • Charlotte Runge
    • Danish Society of Anesthesiology and Intensive Care Medicine DASAIM
    • University of Aarhus
    • The Danish Rheumatism Association

    Investigators

    • Principal Investigator: Johan Sørensen, MD, Aarhus Universitet (Aarhus)

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Charlotte Runge, Medical Doctor, Specialist in Anesthesiology, PhD, Clinical Associate Professor, Regionshospitalet Silkeborg
    ClinicalTrials.gov Identifier:
    NCT05464862
    Other Study ID Numbers:
    • 2022-501206-35-00
    First Posted:
    Jul 19, 2022
    Last Update Posted:
    Jul 19, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 19, 2022